An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs ProPublica FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling Evidence out, ideology in. The FDA's quiet peptide pivot has nothing to do with the data and everything to do with whose side the regulator is choosing. On April 15, 2026, the FDA May Reverse Ban on 14 PeptidesWhat It Means for Your Beauty Routine Allure Why Are People Injecting Themselves with Peptides? The New Yorker